Public Health-Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2019 Jan 23

PMID 30666948

Citations 6

Authors

Adoracion Navarro-Torne

Finnian Hanrahan

Barbara Kerstiens

Pilar Aguar

Line Matthiessen

Affiliations

Soon will be listed here.

Abstract

Influenza virus infections are a major public health threat. Vaccination is available, but unpredictable antigenic changes in circulating strains require annual modification of seasonal influenza vaccines. Vaccine effectiveness has proven limited, particularly in certain groups, such as the elderly. Moreover, preparedness for upcoming pandemics is challenging because we can predict neither the strain that will cause the next pandemic nor the severity of the pandemic. The European Union fosters research and innovation to develop novel vaccines that evoke broadly protective and long-lasting immune responses against both seasonal and pandemic influenza, underpinned by a political commitment to global public health.

Citing Articles

Prophylactic and therapeutic vaccine development: advancements and challenges.

Weerarathna I, Doelakeh E, Kiwanuka L, Kumar P, Arora S Mol Biomed. 2024; 5(1):57.

PMID: 39527305 PMC: 11554974. DOI: 10.1186/s43556-024-00222-x.

Epidemiology of influenza over a ten-year period in Belgium: overview of the historical and current evidence.

Prezzi A, Saelens X, Vandijck D Virol J. 2023; 20(1):271.

PMID: 37990263 PMC: 10664657. DOI: 10.1186/s12985-023-02238-1.

Modelling the impact of universal influenza vaccines on seasonal influenza with different subtypes.

Li R, Li Q, Liu Y, Shen M, Zhang L, Zhuang G Epidemiol Infect. 2022; 149:e253.

PMID: 35903926 PMC: 8697312. DOI: 10.1017/S0950268821002284.

The potential use of digital health technologies in the African context: a systematic review of evidence from Ethiopia.

Manyazewal T, Woldeamanuel Y, Blumberg H, Fekadu A, Marconi V NPJ Digit Med. 2021; 4(1):125.

PMID: 34404895 PMC: 8371011. DOI: 10.1038/s41746-021-00487-4.

Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States.

Talbird S, La E, Carrico J, Poston S, Poirrier J, DeMartino J Hum Vaccin Immunother. 2020; 17(2):332-343.

PMID: 32758069 PMC: 7899694. DOI: 10.1080/21645515.2020.1780847.

References

Kissling E, Rondy M . Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017; 22(7). PMC: 5322188. DOI: 10.2807/1560-7917.ES.2017.22.7.30464. View

Altenburg A, Kreijtz J, de Vries R, Song F, Fux R, Rimmelzwaan G . Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses. 2014; 6(7):2735-61. PMC: 4113791. DOI: 10.3390/v6072735. View

Bernocchi B, Carpentier R, Lantier I, Ducournau C, Dimier-Poisson I, Betbeder D . Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles. J Control Release. 2016; 232:42-50. PMC: 4907310. DOI: 10.1016/j.jconrel.2016.04.014. View

Petrie J, Malosh R, Cheng C, Ohmit S, Martin E, Johnson E . The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine. Clin Infect Dis. 2017; 65(10):1644-1651. PMC: 5850544. DOI: 10.1093/cid/cix608. View

Paules C, Marston H, Eisinger R, Baltimore D, Fauci A . The Pathway to a Universal Influenza Vaccine. Immunity. 2017; 47(4):599-603. DOI: 10.1016/j.immuni.2017.09.007. View

Scorza F, Tsvetnitsky V, Donnelly J . Universal influenza vaccines: Shifting to better vaccines. Vaccine. 2016; 34(26):2926-2933. PMC: 4899887. DOI: 10.1016/j.vaccine.2016.03.085. View

Jabbal-Gill I, Watts P, Smith A . Chitosan-based delivery systems for mucosal vaccines. Expert Opin Drug Deliv. 2012; 9(9):1051-67. DOI: 10.1517/17425247.2012.697455. View

Prager F, Wei D, Rose A . Total Economic Consequences of an Influenza Outbreak in the United States. Risk Anal. 2016; 37(1):4-19. DOI: 10.1111/risa.12625. View

Krammer F . Novel universal influenza virus vaccine approaches. Curr Opin Virol. 2016; 17:95-103. PMC: 4902764. DOI: 10.1016/j.coviro.2016.02.002. View

10.

Manenti A, Tete S, Mohn K, Jul-Larsen A, Gianchecchi E, Montomoli E . Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination. Vaccine. 2016; 35(1):191-198. DOI: 10.1016/j.vaccine.2016.10.024. View

11.

Saadatian-Elahi M, Horstick O, Breiman R, Gessner B, Gubler D, Louis J . Beyond efficacy: The full public health impact of vaccines. Vaccine. 2016; 34(9):1139-47. PMC: 11345718. DOI: 10.1016/j.vaccine.2016.01.021. View

12.

Nair H, Brooks W, Katz M, Roca A, Berkley J, Madhi S . Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011; 378(9807):1917-30. DOI: 10.1016/S0140-6736(11)61051-9. View

13.

Kazaks A, Lu I, Farinelle S, Ramirez A, Crescente V, Blaha B . Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates. BMC Biotechnol. 2017; 17(1):79. PMC: 5681787. DOI: 10.1186/s12896-017-0396-8. View

14.

Iuliano A, Roguski K, Chang H, Muscatello D, Palekar R, Tempia S . Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2017; 391(10127):1285-1300. PMC: 5935243. DOI: 10.1016/S0140-6736(17)33293-2. View

15.

Kreijtz J, Goeijenbier M, Moesker F, van den Dries L, Goeijenbier S, de Gruyter H . Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis. 2014; 14(12):1196-207. DOI: 10.1016/S1473-3099(14)70963-6. View

16.

Nakaya H, Clutterbuck E, Kazmin D, Wang L, Cortese M, Bosinger S . Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc Natl Acad Sci U S A. 2016; 113(7):1853-8. PMC: 4763735. DOI: 10.1073/pnas.1519690113. View

17.

Mina M . Generalized herd effects and vaccine evaluation: impact of live influenza vaccine on off-target bacterial colonisation. J Infect. 2017; 74 Suppl 1:S101-S107. DOI: 10.1016/S0163-4453(17)30199-8. View

18.

de Vries R, de Gruyter H, Bestebroer T, Pronk M, Fouchier R, Osterhaus A . Induction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine. Emerg Infect Dis. 2015; 21(6):1086-8. PMC: 4451911. DOI: 10.3201/eid2106.150021. View

19.

Haq K, McElhaney J . Immunosenescence: Influenza vaccination and the elderly. Curr Opin Immunol. 2014; 29:38-42. DOI: 10.1016/j.coi.2014.03.008. View

20.

Jang Y, Seong B . Options and obstacles for designing a universal influenza vaccine. Viruses. 2014; 6(8):3159-80. PMC: 4147691. DOI: 10.3390/v6083159. View